Cabaletta Bio News Today

Shares of Cabaletta Bio, Inc. (NASDAQ:CABA – Get Free Report) shot up 16.9% during mid-day trading on Wednesday . The company traded as high as $13.09 and last traded at $12.94. 815,014 shares changed hands during trading, a decline of 20% from the average session volume of 1,025,065 shares. The stock had previously closed at […]

Cabaletta Bio, Inc. (NASDAQ:CABA – Get Free Report)’s share price hit a new 52-week low during trading on Wednesday . The company traded as low as $9.52 and last traded at $10.74, with a volume of 594318 shares traded. The stock had previously closed at $9.94. Analyst Ratings Changes A number of equities analysts have […]

Cabaletta Bio, Inc. (NASDAQ:CABA – Get Free Report)’s share price hit a new 52-week low during trading on Wednesday . The company traded as low as $9.52 and last traded at $10.74, with a volume of 594318 shares traded. The stock had previously closed at $9.94. Analyst Ratings Changes A number of equities analysts have […]

HC Wainwright restated their buy rating on shares of Cabaletta Bio (NASDAQ:CABA – Free Report) in a research report released on Friday, Benzinga reports. HC Wainwright currently has a $30.00 price target on the stock. Other equities research analysts have also issued reports about the stock. Wells Fargo & Company increased their target price on […]

/PRNewswire/ -- Lupus advocates from across the nation converged on Capitol Hill for the National Lupus Advocacy Summit May 19-21. Hosted by the Lupus...

The CAR T-cell therapy market for acute lymphoblastic leukemia is poised for substantial growth, driven by the anticipated launch of therapies such as OBECABTAGENE AUTOLEUCEL (OBE-CEL), UCART22

Cabaletta Bio, Inc. (NASDAQ:CABA – Get Free Report) has earned a consensus rating of “Buy” from the nine ratings firms that are currently covering the company, Marketbeat reports. Nine investment analysts have rated the stock with a buy rating. The average 1-year price target among brokerages that have covered the stock in the last year […]

BioPharma

Allspring Global Investments Holdings LLC reduced its holdings in Cabaletta Bio, Inc. (NASDAQ:CABA – Free Report) by 71.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,164 shares of the company’s stock after selling 2,972 shares during the quarter. Allspring […]

With equipment that promises to produce 10 times more therapies, the deal with Cellares is hoped to make BSM's CAR-T ambitions more scalable and affordable